Pulmonx Corporation: Pulmonx Announces Publication of CONVERT Trial Results for AeriSeal System
Pulmonx Corporation (Nasdaq: LUNG) announced the publication of CONVERT Trial results for its AeriSeal System, showing 75.8% of patients with severe emphysema and collateral ventilation had successful treatment. The study suggests the system could enable subsequent treatment with Zephyr Valves, improving lung function and quality of life. Pulmonx is now conducting the CONVERT II Pivotal Trial to support a U.S. FDA Premarket Approval application for the AeriSeal System.
How this was made
The 30-second read
Why it matters
The publication provides concrete clinical performance for converting CV+ to CV- and reports subsequent valve outcomes, strengthening the scientific rationale for the ongoing CONVERT II pivotal IDE trial aimed at US FDA PMA support.
Market read
Traders may reassess the probability of regulatory success and commercial expansion for AeriSeal-enabled Zephyr Valve treatment based on newly published conversion and follow-on valve outcome data.
What to watch
US PMA timing and the operational execution of CONVERT II enrollment and follow-on valve outcomes may matter more than the published conversion endpoint alone.
Background
Pulmonx’s AeriSeal System is intended to close collateral ventilation channels so patients with severe emphysema can become eligible for Zephyr Endobronchial Valve treatment.
Ticker impact
Pulmonx published CONVERT Trial results showing AeriSeal converted collateral-ventilation positive lobes to collateral-ventilation negative in 75.8% of evaluable patients.
Likely positive bias as the market prices improved probability of expanding Zephyr Valve eligibility via AeriSeal conversion results.
The article discloses specific conversion and follow-on valve outcome rates and reiterates CONVERT II enrollment intended to support a US PMA application, which are direct catalysts for the company’s regulatory and commercial narrative.
Market effects
Reinforces the COPD interventional device theme that patient selection and procedural sequencing can expand treatable populations.
Primarily US-listed biotech/device sentiment, with trial sites in Europe and Australia.
Supports a global regulatory and adoption narrative for bronchoscopic lung volume reduction technologies.
Counterpoint
Because CONVERT is open-label and single-arm, investors may discount the conversion rate until CONVERT II provides pivotal, regulator-grade evidence.
Key entities
- companyPulmonx Corporation
Nasdaq-listed developer of minimally invasive COPD treatments, including Zephyr Endobronchial Valves and the AeriSeal System.
- productAeriSeal System
Bronchoscopic system evaluated in CONVERT to convert collateral ventilation status from CV+ to CV-.
- clinical_trialCONVERT Trial
Prospective, open-label, multicenter, single-arm study (NCT04559464) evaluating AeriSeal conversion followed by Zephyr Valve treatment.
- clinical_trialCONVERT II Pivotal Trial
Multinational pivotal IDE study (NCT06035120) enrolling about 200 patients, targeting US FDA PMA support using six-month results.

